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Abstract
Introduction Oxidative stress is involved in the development of
secondary tissue damage and organ failure. Micronutrients
contributing to the antioxidant (AOX) defense exhibit low plasma
levels during critical illness. The aim of this study was to
investigate the impact of early AOX micronutrients on clinical
outcome in intensive care unit (ICU) patients with conditions
characterized by oxidative stress.
Methods We conducted a prospective, randomized, double-
blind, placebo-controlled, single-center trial in patients admitted
to a university hospital ICU with organ failure after complicated
cardiac surgery, major trauma, or subarachnoid hemorrhage.
Stratification by diagnosis was performed before randomization.
The intervention was intravenous supplements for 5 days
(selenium 270 μg, zinc 30 mg, vitamin C 1.1 g, and vitamin B1
100 mg) with a double-loading dose on days 1 and 2 or
placebo.
Results Two hundred patients were included (102 AOX and 98
placebo). While age and gender did not differ, brain injury was
more severe in the AOX trauma group (P  = 0.019). Organ
function endpoints did not differ: incidence of acute kidney
failure and sequential organ failure assessment score decrease
were similar (-3.2 ± 3.2 versus -4.2 ± 2.3 over the course of 5
days). Plasma concentrations of selenium, zinc, and glutathione
peroxidase, low on admission, increased significantly to within
normal values in the AOX group. C-reactive protein decreased
faster in the AOX group (P = 0.039). Infectious complications
did not differ. Length of hospital stay did not differ (16.5 versus
20 days), being shorter only in surviving AOX trauma patients (-
10 days; P = 0.045).
Conclusion The AOX intervention did not reduce early organ
dysfunction but significantly reduced the inflammatory response
in cardiac surgery and trauma patients, which may prove
beneficial in conditions with an intense inflammation.
Trials Registration Clinical Trials.gov RCT Register:
NCT00515736.
Introduction
Critically ill patients are generally exposed to an increased oxi-
dative stress, which is proportional to the severity of their con-
dition [1,2]. A network of functionally overlapping antioxidant
(AOX) defense mechanisms aims at protecting cells from
reactive oxygen and nitric oxide species. It is formed by trace-
element-dependent enzymes such as superoxide dismutase,
catalase, and glutathione peroxidase (GPX) (selenium, zinc,
manganese, copper, and iron), thiol donors, and their
AKI = acute kidney injury; ANOVA = analysis of variance; AOX = antioxidant; BP = bodily pain; CI = confidence interval; CRP = C-reactive protein; 
EN = enteral nutrition; FiO2 = fraction of inspired oxygen; GCS = Glasgow Coma Scale; GH = general health perception; GPX = glutathione perox-
idase; ICU = intensive care unit; ISS = Injury Severity Score; iv = intravenously; MOS SF-36 = Medical Outcome Study Short Form 36-item health 
survey; PaO2 = arterial partial pressure of oxygen; PF = physical functioning; PN = parenteral nutrition; RP = role functioning-physical; RR = relative 
risk; SAH = subarachnoid hemorrhage; SAPS = Simplified Acute Physiology Score; SF-36 = Short Form 36-item health survey; SIRS = systemic 
inflammatory response syndrome; SOFA = sequential organ failure assessment.Critical Care    Vol 12 No 4    Berger et al.
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precursors. The vitamins E, C, and β-carotene with other mol-
ecules (urate and albumin) also contribute to AOX defense
[3]. The more severe the insult and the sepsis, the larger the
depletion of AOXs appears to be [1,4,5]. The micronutrients
have the capacity to downregulate nuclear factor-kappa-B
activation and subsequent cytokine production [6]. Hence,
micronutrient deficiency favors the persistence of inflammation
and the propagation of lipid peroxidation and other free-radi-
cal-mediated damage, contributing to organ dysfunction and
failure.
The selenium status of the general population in Europe is
often suboptimal before acute illness [7,8]. Nearly all patients
with sepsis or shock exhibit early low plasma selenium levels,
which are correlated with the severity of inflammation and sub-
sequent outcome [9]. Micronutrient status deteriorates during
acute illness despite standard micronutrient intake [10]. Some
therapies, such as continuous renal replacement, increase
micronutrient losses and may further reduce micronutrient
availability [11]. In addition, the acute-phase response causes
redistribution of micronutrients from the vascular compartment
to the liver and the reticuloendothelial system, depleting the
circulating micronutrients [12].
Much clinical research has focused on the AOX micronutri-
ents vitamins C and E, copper, selenium, and zinc. Most clini-
cal trials have been carried out in sepsis, trauma, and burns,
which are characterized by intense oxidative stress and inflam-
matory response. In a systematic review of randomized studies
[13], overall AOX supplements were associated with a signif-
icant reduction in mortality (relative risk [RR] 0.65, 95% confi-
dence interval [CI] 0.53 to 0.80; P < 0.0001) but had no effect
on infectious complications. In further subgroup analyses,
selenium supplementation was associated with a nonsignifi-
cant reduction in mortality (RR 0.59, 95% CI 0.32 to 1.08; P
= 0.09). Recent studies of selenium, copper, and zinc supple-
ments in burn patients [14] and high-dose selenium in severe
sepsis [15] confirm these positive observations: the reinforce-
ment of the AOX defenses is a plausible mechanism [3]. The
population likely to benefit from such interventions has not
been defined yet. While selenium supplementation, or substi-
tution, is rational in the European selenium-depleted areas [7],
the physiology of the endogenous AOX system should be con-
sidered. AOX defenses act as a network [16]. The AOXs
therefore should probably be provided as a combination to
avoid disequilibrium in the system, especially if several micro-
nutrients are lost simultaneously as in trauma, burns, and renal
replacement therapy.
The present trial aimed at testing the hypothesis that the early
administration of an AOX micronutrient combination including
selenium would improve clinical outcome in selected groups
of critically ill patients admitted for conditions characterized by
local or systemic oxidative stress [17,18] and at risk of micro-
nutrient depletion, by reinforcing the endogenous AOX
defenses and reducing organ failure.
Materials and methods
Study design
We conducted a prospective, randomized, double-blind, pla-
cebo-controlled, single-center trial with the approval of the
institutional ethics committee.
Patient population
Two hundred consecutive patients admitted to the intensive
care unit (ICU) at the University Hospital (Centre Hospitalier
Universitaire Vaudois) of Lausanne were enrolled from January
2003 through September 2004. Three conditions admitted
with organ failure deemed likely by the medical team to require
at least 48 hours of ICU treatment were considered: cardiac
valve or coronary bypass surgery with postoperative cardiac or
respiratory failure, major trauma (with or without brain injury)
with an Injury Severity Score (ISS) of greater than 9, and
severe subarachnoid hemorrhage (SAH) (that is, World Fed-
eration of Neurological Surgeons grades 3, 4, and 5) [19].
These three pathologies were investigated based on the dem-
onstration of oxidative stress-related damage [17,18,20].
Exclusion criteria were absence of consent, participation in
another study, liver cirrhosis or major burns, and life expect-
ancy of less than 48 hours or a lack of commitment to full
aggressive care (anticipated withholding or withdrawing of
treatments in the 48 hours).
Severity of condition
Cardiac surgery patients' preoperative status was assessed
using the Parsonnet score [21] and the Euroscore [22].
Trauma severity was based on the ISS [23] and the Glasgow
Coma Scale (GCS) score on admission and at discharge.
Severity of physiological condition was determined by the first
24 hours' Simplified Acute Physiology Score (SAPS II) [24]
and the daily sequential organ failure assessment (SOFA) [25]
scores. Pre-existing renal failure was defined as a preadmis-
sion creatinine clearance of less than 60 mL/minute (meas-
ured or calculated with the Cockcroft-Gault equation on
preoperative creatinine value [26]).
Randomization
After stratification for diagnosis, the patients were randomly
assigned by the pharmacist to either AOX micronutrient or pla-
cebo group, using a random list with a four-block allocation.
Patients, clinicians, and investigators were blinded to the treat-
ment. Black plastic bags covered the solutions, and colored
tubing was used for infusion. Trace elements and vitamins
were prepared in separate bags. Labels carried the patients'
name, study number, and whether the content was supposed
to be vitamin or trace element. The ethics committee, consid-
ering the limited risks associated with the micronutrient sup-
plements, delivered a waiver of consent for the study enabling
the randomization, the initiation of the intervention, and the firstAvailable online http://ccforum.com/content/12/4/R101
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blood sampling. Oral consent was requested within 48 hours
and a written consent within 96 hours. The patient was asked
first whether he/she was not competent at that time, and pro-
visory consent was requested among the relatives and con-
firmed by the patient once his/her condition had recovered.
Intervention
Intervention consisted of delivering either AOX supplement or
placebo for 5 days starting within 24 hours of admission. The
supplementation consisted of an initial loading dose (double
dose for 2 days) followed by 3 days of therapeutic dose (Table
1). The intervention solutions were infused alternately intrave-
nously (iv) over the course of 10 to 12 hours each (vitamins
during the daytime and trace elements over night). Products
were Decan®, Sodium selenite®, and Zinc gluconate® (Labo-
ratoires Aguettant, Lyon, France), Soluvit® + Vitalipid® (Fre-
senius Kabi AG, Bad Homburg, Germany), vitamin B1 as
Benerva® and vitamin C (Streuli Pharma AG, Uznach, Switzer-
land), and α-tocopherol as Ephynal® (Roche, Basel, Switzer-
land). Vitamin E was delivered by nasoenteric tube. Besides
the intervention solution, all patients received the ICU's 'stand-
ard vitamin profile' consisting of 100 mg thiamine and 500 mg
vitamin C iv per day. In case of suspicion of alcohol abuse, an
additional 100 mg thiamine was delivered. The 11 patients
requiring parenteral nutrition (PN) for a total of 82 days (3 in
the placebo group and 8 in the AOX group; P = 0.13) received
the recommended doses of micronutrients for PN in addition
to the 'intervention solution' (1 ampule of Soluvit® + 1 ampule
of Vitalipid® + 1 ampule of Decan®) as part of standard care.
In patients on full enteral nutrition (EN), one multivitamin and
mineral tablet (Supradyn®; Roche) were delivered per day with
EN (these micronutrients are not included in Table 1).
Outcome variables
The primary outcome variable was a change in the acute kid-
ney injury (AKI) score. Changes in organ function monitored by
the SOFA score [25] were considered as an important sec-
ondary endpoint but were not used to calculate the sample
size. At the time of the trial initiation, the SOFA scores' capac-
ity to detect changes in mainly cardiac and trauma patients
was not known. Renal failure affects about 35% of critically ill
patients [27] and remains a major determinant of length of
hospital stay [28]. Three levels of severity were considered: (a)
AKI based on acute alterations of urine output according to the
AKI Network [29] (stage 1: urine output of less than 0.5 mL/
kg for 6 hours; stage 2: urine output of less than 0.5 mL/kg for
12 hours; and stage 3: urine output of less than 0.3 mL/kg for
12 hours or anuria for 12 hours). Acute renal failure was further
defined by a plasma creatinine increase of (b) 50 or (c) 90
μmol/L [30]. The SOFA score was further used to test global
organ dysfunction: this score ascribes a value of severity of
organ failure from 0 to 4 for cardiovascular, respiratory, renal,
hepatic, nervous, and coagulation failure (maximum score of
24). The SOFA score was repeated daily until day 5 or until
discharge from the ICU. Secondary outcome variables
included the daily worst arterial partial pressure of oxygen/
fraction of inspired oxygen (PaO2/FiO2) ratio and mechanical
ventilator dependence. The number of ventilator-free days to
day 30 was defined as the number of days of unassisted
breathing to day 30 after randomization, assuming a patient
survives and remains free of invasive or noninvasive assisted
breathing for at least 2 consecutive calendar days after extu-
bation, whatever the vital status at day 30. Infectious compli-
cations, duration of ICU stay (counted by quarter-days
rounded to the closest 6 hours), and ICU, hospital, and 3-
month mortality rates were recorded. All infectious complica-
tions were recorded using the Centers for Disease Control
and Prevention definitions [31], with special emphasis on pul-
monary infections: pneumonia was defined as the combination
of systemic inflammatory response syndrome (SIRS) with a
new infiltrate on the chest x-ray (or progression of an infiltrate),
a new or persistent hypoxemia, and purulent sputum. A stand-
ardized questionnaire was used to assess quality of life at 3
months: the Medical Outcome Study Short Form 36-item
health survey (MOS SF-36). The patients were contacted by
telephone, and the questionnaire was limited to the physical
components: physical activity (physical functioning [PF]:
scores 10 to 30), limitation due to physical status (role func-
tioning-physical [RP]: scores 4 to 8), pain (bodily pain [BP]:
scores 2 to 12), perceived health (general health perception
[GH]: scores 5 to 25), and summary physical score of the
MOS SF-36 were analyzed [32]. Due to interview difficulties,
psychological components were not elicited.
Laboratory determinations
Plasma creatinine, C-reactive protein (CRP), glucose, albumin,
leukocytes, and platelets were determined daily for clinical
purposes, and aspartate amino transferase, alanine amino
transferase, and urate were determined three times weekly
using standard clinical laboratory methods. Blood samples
were collected on admission (day 0) and on day 5 (end of sup-
plementation) to determine plasma zinc and selenium: analysis
was in duplicate by inductively coupled plasma mass spec-
trometry (Plasmaquad 3 ICP-MS; VG Elemental, Winsford,
Table 1
Total antioxidant micronutrient doses in supplements during 
the first 5 days
Micronutrient Days 1 and 2 Days 3–5
Zinc, mg 60 30
Selenium, μg 540.4 270.2
Vitamin C, mg 2,700a 1,600a
Vitamin B1, mg 305a 102.5
Vitamin E enteral, mg 600 300
Vitamin E iv, mg 12.8 6.4
aIncludes the standard supplementation policy that was provided to 
both groups (500 mg vitamin C/day for 5 days and 100 mg vitamin 
B1/day for 3 days). iv, intravenously.Critical Care    Vol 12 No 4    Berger et al.
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Cheshire, UK) using aqueous inorganic standards. All plasma
specimens were diluted in 1% nitric acid/0.2% n-butanol/
0.2% n-propanol and 10 parts per billion indium as internal
standard [33]. Plasma GPX was determined by the RANSEL
method (Randox Laboratories, Belfast, UK).
Nutritional support
EN or PN was initiated on a clinical basis, according to the
unit's clinical protocols with the standard ICU solutions. The
energy target was calculated as 1.2 times the predicted rest-
ing energy from the Harris and Benedict equation in cardiac
surgery and SAH patients and as 30 kcal per kg body weight
in trauma patients. EN was considered first, and PN was used
only when EN was contraindicated. Glucose-insulin infusions
were delivered in those at risk of ischemic postoperative car-
diac failure. The cumulated energy balance was calculated at
5 days and at the end of the ICU stay. For those patients dis-
charged before day 5, the energy intakes were recorded until
day 5.
Blood glucose control
The blood glucose target of 5 to 8 mmol/L was achieved by
means of a continuous insulin infusion. For every patient, a
mean of all blood glucose values per 24 hours was calculated
during the first 5 days. The 24 hours' insulin doses were
recorded. The variables were retrieved from the database of
our clinical information system (MetaVision®;  iMD  soft, Tel
Aviv, Israel).
Statistical analysis
As there were no data available in the literature on the
expected impact of supplementation on the SOFA score, the
sample size was determined based on an expected reduction
of acute renal failure of 20% defined as a creatinine increase
of 50 μmol/L [34], an organ failure that has a significant impact
on outcome. We realized an a priori power analysis, expecting
an acute renal failure incidence of 30% and a 50% reduction,
using an alpha level of 0.05 and a power of 0.9: these numbers
resulted in a sample size of 186 (rounded to 200). A safety
committee was formed to address safety issues, but it could
not modify the sample size. After 60 and 120 patients, respec-
tively, two meetings were conducted in order to detect over-
mortality and adverse events: the two intermediate analyses
did not detect any difference between groups.
Analysis was by intent to treat. Data are presented as mean ±
standard deviation or as median and range when specified.
Demographic data, energy balance, and baseline variables
were analyzed by one-way analysis of variance (ANOVA) as
they were normally distributed; two-way ANOVAs were used
for variables repeated over time such as SOFA score, PaO2/
FiO2 ratios, laboratory variables, and insulin dose. Post hoc
comparisons were carried out by Dunnett test (effect of time
versus baseline in each group) or Scheffe test (between-
group comparisons at the same time point), where appropri-
ate. Rank tests were used for nonparametric variables. Kaplan-
Meier analysis was applied to length of hospital stay: nonsur-
vivors were considered as never achieving the event of interest
(discharge) and censored at the end of evaluation period. Mul-
tiple and simple logistic regressions between variables were
calculated. Significance was considered at a P value of less
than 0.05; trends were considered up to a P value of less than
0.25. The statistical package was JMP® version 5.1. (SAS
Institute Inc., Cary, NC, USA).
Results
Altogether, 200 patients completed the trial, resulting in 1,609
days of ICU treatment included in the analysis (Figure 1). A fur-
ther 28 patients were considered but did not fulfill the study
criteria, were deemed too severe within 24 hours with limita-
tion of treatment, or refused consent. Table 2 shows the global
patient characteristics and their distribution in the three diag-
nostic categories: age, gender ratio, SAPS II, body mass
index, and SOFA score did not differ between the AOX and
placebo groups, while the cardiac surgery patients were sig-
nificantly older than both trauma and SAH groups. The gender
ratio differed in trauma patients (predominance of males) and
in the SAH group (predominance of females). The mean SAPS
II was 38 ± 13 (predicted mortality 24.8%) and was highest in
the cardiac surgery patients. Some heterogeneity was
observed despite the randomization [35]. The cardiac scores
did not differ significantly between groups: median Parsonnet
was 15.5 (range 3 to 53) and median Euroscore was 8 (range
1 to 17). While severity of disease was similar in the cardiac
and SAH treatment groups, there were significant differences
regarding severity of brain injury between the trauma AOX and
placebo patients (Table 3). Severity of brain injury was worse
in the AOX subgroup compared with placebo patients, as
reflected by a lower admission GCS score (of 8) (P = 0.11),
with more severe SAPS (due to the low GCS score; P = 0.04)
and brain ISS (P = 0.019) and worse admission neurological
SOFA scores (P = 0.012). On discharge, GCS score differed
significantly among brain-injured patients, with 11.1 ± 4.2 in
the AOX group versus 13.6 ± 4.2 in the placebo group (P =
0.03), while there was no difference in the 27 patients without
brain injury (15 ± 0 and 14.9 ± 0.3, respectively). These differ-
ences were associated with 6 versus 2 deaths in the placebo
group (P = 0.16).
Protocol violations
There were 47 protocol violations (19 in the placebo group
and 28 in the AOX group), evenly distributed among the three
diagnostic categories (18 in cardiac, 22 in trauma, and 7 in
SAH). Among these, 25 were considered nonsignificant as
they reinforced the intervention effect (by increasing the doses
of AOX), while 22 violations reduced the difference between
groups (5 in placebo patients who received 1 or 2 doses of
AOX, 17 in the AOX group by deletion of 1 to 3 doses of sup-
plement). All patients were included in the intent-to-treat
analysis.Available online http://ccforum.com/content/12/4/R101
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Outcome variables
Kidney function
Pre-existing renal failure was present in 30.5% of patients,
being more frequent in the cardiac surgery patients (P  <
0.001) but in only 9.5% of SAH patients (Table 4). AKI of any
grade developed in 66 (33%) patients (30 and 36, or 29%
and 37%, respectively, in AOX and placebo groups; P  =
0.11); it was most frequent in the cardiac patients (P  <
0.0001) and least frequent in SAH (2 in AOX and 1 in pla-
cebo). The more severe grades of renal failure (increases of 50
μmol/L in 32 patients and of 90 μmol/L in 16 patients) did not
Table 2
Patient characteristics on admission with detail of the diagnostic categories
Variable All Complex cardiac surgery Trauma Subarachnoid hemorrhage
Number 200 113 66 21
AOX Placebo AOX Placebo AOX Placebo AOX Placebo
N u m b e r 1 0 29 85 75 6 3 4 3 2 1 1 1 0
Gender, male/female 127/73 70/43a 52/14a 5/16a
Age, years 59 ± 19 70 ± 10a 40 ± 19a 54 ± 9
58 ± 19 59 ± 20 69 ± 8 71 ± 11 40 ± 19 40 ± 19 54 ± 7 53 ± 10
Weight, kg 74 ± 15 75 ± 16 75 ± 13 68 ± 12
74 ± 15 74 ± 15 75 ± 16 74 ± 17 72 ± 12 77 ± 13b 72 ± 13 64 ± 9c
Body mass index, kg/m2 25.8 ± 4.6 26.5 ± 5.0 24.9 ± 3.9 24.5 ± 3.4
25.8 ± 4.8 25.7 ± 4.3 26.7 ± 5.3 26.2 ± 4.7 24.2 ± 3.8 25.6 ± 3.9 25.2 ± 4.0 23.7 ± 2.5
SAPS II 37.5 ± 12.7 39.3 ± 10.4d 35.7 ± 15.4d 33.9 ± 13.6d
38.4 ± 12.7 36.6 ± 12.8 38.4 ± 9.3 40.3 ± 11.4 39.9 ± 17.0 31.1 ± 12.2e 33.6 ± 12.0 34.2 ± 9
SOFA score at admission 8.3 ± 2.5 9.1 ± 1.7a 7.5 ± 3.1a 6.3 ± 2.9a
8.2 ± 2.8 8.3 ± 2.2 8.8 ± 1.7 9.3 ± 1.6 7.8 ± 3.5 7.1 ± 3.2 5.7 ± 3.8 6.9 ± 1.4
aP < 0.0001; bP = 0.08; cP = 0.14; dP = 0.07; eP = 0.01. Superscripts a and d refer to comparison between diagnostic categories. Superscripts 
b, c, and e refer to comparison between AOX and placebo (= P) groups. SAPS, Simplified Acute Physiology Score; SOFA, sequential organ 
failure assessment.
Table 3
Specific severity indices in the trauma patients on enrollment, according to presence of brain injury
Trauma (n = 66) AOX Placebo P value
Number 34 32
Injury Severity Score, all 30.1 ± 9.8 28.3 ± 10.4 NS
Brain injury (n = 39; 20/19) 31.0 ± 11.0 28.7 ± 11.9 NS
No brain injury (n = 27; 14/13) 28.9 ± 7.9 27.6 ± 8.1 NS
Injury Severity Score brain, in brain-injured 14.5 ± 4.9 10.8 ± 4.5 0. 019
Glasgow Coma Scale score initial, all 10.4 ± 4.9 11.8 ± 4.3 0.16
Brain injury 7.4 ± 4.3 9.7 ± 4.8 0.11
No brain injury 14.6 ± 0.6 14.8 ± 0.8 NS
SAPS II 39.9 ± 17.0 31.1 ± 12.2 0.04
SOFA score, neuro section 1.62 ± 1.7 0.97 ± 1.2 0.085
Brain injury 2.5 ± 1.6 1.38 ± 1.2 0.012
No brain injury 0.2 ± 0.4 0.2 ± 0.6 NS
Data are presented as mean ± standard deviation. P values refer to comparison between the antioxidant (AOX) and placebo groups. NS, not 
significant; SAPS, Simplified Acute Physiology Score; SOFA, sequential organ failure assessment.Critical Care    Vol 12 No 4    Berger et al.
Page 6 of 13
(page number not for citation purposes)
differ between AOX and placebo groups. Altogether, 7
patients required transient continuous renal replacement ther-
apy (6 in AOX and 1 in placebo; P = 0.05), of whom 6 suffered
pre-existing chronic renal failure. After censoring for prior
chronic renal failure, there was no significant difference
between groups. Persistent renal failure was observed in 11
patients (not significant between groups).
Sequential organ failure assessment scores
Admission scores were elevated but did not differ between
treatment groups, although they differed between diagnostic
categories (Table 2). The associated initial number of organ
failures was also similar (median 3, range 1 to 6), as was the
number of severe organ failures (median two organs with a
SOFA score of 3 or 4). The SOFA score decreased signifi-
cantly over time (P < 0.0001) in both groups (Figure 2), with
no significant difference between AOX and placebo groups.
Infections and pneumonia
Seventy patients suffered infectious complications (not signif-
icant between groups): the incidence of pneumonia was low
(episodes n = 32) and did not differ between groups (Table 4).
The likelihood to develop pneumonia increased with energy
deficit per kilogram by day 5 (P = 0.005) as did that of having
any infection (P  = 0.0015). The lowest infection rate was
observed in SAH patients with 13 infections (5 in AOX and 8
in placebo) in 10 patients.
Length of mechanical ventilation
Despite lower mean values in the AOX group, the differences
did not reach significance (Table 5). The PaO2/FiO2 ratio
increased over time (P < 0.0001) in all cardiac and trauma
patients, with a trend to faster increase in the AOX patients
(data not shown; P = 0.109). The number of ventilator-free
days did not differ.
Length of stay
Stay in the ICU did not differ significantly between groups,
although mean lengths of stay were 0.6 and 1.3 days shorter
in the AOX group in the surviving cardiac and trauma patients,
respectively. The length of hospital stay was 3 days shorter
overall in the AOX group, being 13 days shorter in the AOX
trauma patients compared with placebo (P = 0.016) and 11
days shorter in those AOX trauma patients without brain injury
(P  = 0.053). Gender did not influence outcome. Figure 3
shows that the presence of brain injury was an important
determinant of hospital stay.
Mortality
Mortality was lower than predicted and did not differ between
the groups. While the overall calculated probability of death in
the cardiac patients was 15.3% by Euroscore, the observed
hospital mortality was 10.6%. In trauma patients, mortality was
12.1%: while mortality between AOX and placebo groups did
not differ when all trauma patients were considered (Table 4),
the number of deaths tended to be higher in the AOX brain-
injured trauma group (P = 0.076), with 5 out of 6 deaths
directly caused by severe brain injury. Adverse events were
collected and did not differ between groups.
Biological variables
Trace elements and glutathione peroxidase
Analysis was done in cardiac surgery and trauma patients.
Mean selenium, zinc, and GPX concentrations were in the
lower normal ranges on admission (not significant between
groups) (Figure 4), reflecting typically European conditions,
with 69% of selenium and 80% of GPX values being below
the lower reference value. The supplements significantly
increased plasma concentrations of both selenium and zinc to
within the normal ranges. The GPX activity increased with
plasma selenium.
Plasma C-reactive protein
Mean CRP value peaked by day 2 and decreased in both AOX
and placebo groups thereafter (Table 5), and significantly
lower values were observed in the AOX patients. The strong-
est CRP increases were observed after cardiac surgery and in
trauma patients, with a faster decay in the AOX cardiac
patients. The SAH patients' mean peak and overall CRP val-
ues were significantly lower than in the two other categories
(P = 0.039).
Glucose control
The mean blood glucose value did not differ significantly
between groups; values from days 0 to 5 were 8.2 ± 2.8, 7.2
± 1.8, 6.7 ± 1.4, 7.0 ± 1.6, 6.8 ± 1.4, and 7.1 ± 1.8 mmol/L
in the AOX group versus 8.9 ± 2.7, 7.4 ± 1.6, 7.2 ± 1.8, 7.1
± 2.2, 7.1 ± 1.7, and 7.0 ± 1.6 mmol/L in the placebo group.
The mean blood glucose over the first 5 days differed by diag-
nostic category (P < 0.0001), being highest in the cardiac sur-
gery (mean of all values = 8.9 mmol/L), intermediate in trauma
Figure 1
Enrollment diagram Enrollment diagram. ICU, intensive care unit.Available online http://ccforum.com/content/12/4/R101
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Table 4
Outcome variables with detail of cardiac and trauma patients
Variable All Cardiac surgery Trauma
AOX Placebo AOX Placebo AOX Placebo
Number 200 113 66
N u m b e r 1 0 2 9 8 5 75 63 4 3 2
Prior renal failure 61 (30.5%) 49 (43.4%)a 10 (15.1%)
25 36 20 29 6 4
Acute kidney injury 66 (33%) 50 (44.2%)a 13 (19.7%)
29 (30%) 36 (37%) 21 (37%) 29 (52%)b 76
ARF increase of 50 μmol/L 32 (16%) 29 (27.5%)a 3 (15.2%)
15 (15%) 17 (17% 13 (23% 16 (29%) 2 1
ARF increase of 90 μmol/L 16 (8%) 15 (13.3%)a 1 (1.5%)
7 (7%) 9 (9%) 6 (11% 9 (16%) 1 0
CVVH 7 (3.5%) 6 (5.3%) 1 (1.5%)
61 c,d 511 0
Persistent renal failure 11 (5.5%) 10 (8.8%) 1 (1.5%)
4 (4%) 7 (7%) 3 (5%) 7 (13%)e 10
Ventilator-free days 26.3 ± 5.5 26.6 ± 5.3 25.2 ± 6.3
26.1 ± 5.7 26.6 ± 5.2 25.9 ± 6.7 27.3 ± 3.3e 25.5 ± 4.6 24.9 ± 7.7
Infections (patients with) 70 30 30
36 34 14 16 17 13
Infectious episodes 91 39 39
45 46 19 20 21 18
Pneumonia episodes 30 16 14
14 16 7 9 7 7
Length of stay, days
In the ICU 5.6 ± 5.5 5.2 ± 5.1 6.3 ± 6.5
5.8 ± 5.4 5.4 ± 5.7 5.8 ± 6.0 4.7 ± 4.0 5.8 ± 4.4 6.8 ± 8.3
In intermediate care 5.0 ± 5.5 3.6 ± 3.5 6.5 ± 7.2
4.5 ± 4.9 5.5 ± 6.0 3.3 ± 4.2 3.4 ± 4.1 5.9 ± 7.1 7.1 ± 7.4
In the hospital 24 ± 20 19 ± 13 32 ± 22
23 ± 20 26 ± 20 20 ± 14 19 ± 13 26 ± 19 39 ± 24f
Deaths
In the ICU 14 (7%) 11 (9.7%) 2 (3%)
8 5 652 0 g
In hospital 23 (11.5%) 12 (10.6%) 8 (12.1%)
1 4 9 866 2 g
At 3 months 25 (12.5%) 16 (14.2%) 8 (12.1%)
14 11 8 8 6 2g
Data are presented as number (percentage) and mean ± standard deviation. aP < 0.001. bP = 0.109. cP = 0.05. dSee comment in Results section. eP = 
0.17. fP = 0.016. gP = 0.16. Superscript a refers to comparison between diagnostic categories. Superscripts b, c, e, f, and g refer to comparison between 
antioxidant (AOX) and placebo groups. ARF, acute renal failure; CVVH, continuous veno-venous hemofiltration; ICU, intensive care unit.Critical Care    Vol 12 No 4    Berger et al.
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(8.6 mmol/L), and lowest in SAH (6.2 mmol/L) and decreasing
significantly over time (P = 0.005), the decrease being similar
in the AOX and placebo groups.
Insulin requirements
Insulin requirements per day during the first 48 hours were ele-
vated in cardiac surgery patients (not significant between
groups) and resulted mainly from the use of glucose-insulin
infusions in the cardiac patients, which was dictated by the
patients' immediate postoperative condition. The insulin
requirements were significantly lower in trauma and SAH
patients (P < 0.0001), being lowest in the SAH patients, with
no difference between groups.
Nutritional support
Total energy delivery during the first 5 days was hypocaloric in
most patients, and the progression of energy delivery was
slower than recommended by our protocol. Eleven patients
required PN for 3 to 11 days. The mean and median cumulated
energy balances on day 5 were negative and did not differ sig-
nificantly between groups (-5,415 kcal in placebo versus -
5,680 kcal in AOX).
Short Form 36-item health survey
SF-36 could be retrieved in 140 (70%) of the 174 surviving
patients (1 cardiac placebo patient died during the fourth
month), including 68 AOX and 72 placebo patients (88 car-
diac, 36 trauma, and 16 SAH). The 34 missing patients were
not feeling well enough to answer (n = 11) or were having lan-
guage problems (n = 7) or were lost to follow up (altogether,
n = 17). Physical activity score (PF) tended to be higher in
AOX (24.1 ± 4.9 versus 22.8 ± 5.7; P = 0.14). Physical limi-
tation (RP: 5.8 ± 1.4 versus 5.5 ± 1.5; not significant), physi-
cal pain (BP: 8.9 ± 2.4 versus 9.0 ± 2.7; not significant), and
perceived health (GH: 18.9 ± 4.5 versus 19.2 ± 4.1; not sig-
nificant) did not differ. Perceived evolution of health after the
hospital discharge (HT = Health Transition) was significantly
better in the AOX patients, with significantly more frequent rat-
ings 'better' and 'rather better' (P = 0.01).
Discussion
The main result of the present trial is that AOX micronutrient
supplements provided for 5 days to critically ill patients did not
achieve any significant impact on organ function (acute kidney
failure or SOFA score of the first 5 days) despite trends to less
renal injury and residual persistent renal failure in the AOX
group. The intervention was associated with a significant
blunting of the inflammation, reflected by lower CRP levels in
the AOX group. Significant reduction of hospital stay was
observed only in the trauma group. There was no impact on
mortality.
The three diagnostic categories of patients were selected
based on the demonstration of the involvement of oxidative
stress in their clinical course [17,18], but during the study the
three categories behaved differently regarding the systemic
inflammatory response. We indeed observed significant differ-
ences in the magnitude of the CRP response between the
three categories; the complicated cardiac and trauma patients
exhibited an intense inflammation, whereas the SAH caused
only a limited plasma CRP response, as observed by others
[36]. This difference in the inflammatory pattern enables us to
generate some hypotheses: (a) in the presence of an intense
SIRS, such as in trauma patients, the AOX cocktail
downregulated the inflammatory response with clinically
observable effects, while (b) there was no detectable biologi-
cal or clinical effect in those patients with limited SIRS. Con-
sidering that SIRS is deleterious since it promotes organ
failure [37], such a modulation is potentially beneficial. Indeed,
trauma patients appeared to benefit significantly as reflected
by the reduction of their hospital stay, which was associated
with better perceived health according to the SF-36 score at
3 months. This was particularly true in non-brain-injured
patients; in those with brain injury, the conclusion is more
Figure 2
Evolution of the sequential organ failure assessment (SOFA) scores in  all patients by group with the detail of cardiac and trauma patients Evolution of the sequential organ failure assessment (SOFA) scores in 
all patients by group with the detail of cardiac and trauma patients.Available online http://ccforum.com/content/12/4/R101
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awkward due to the higher severity of injury on admission in
the AOX group. The improvement of outcome is also in agree-
ment with the reduction of organ alterations observed by Nath-
ens and colleagues [38] in a large vitamin intervention trial in
trauma patients. Animal data show that, during the early phase
after a brain trauma, the oxidative stress is associated with vita-
min E and selenium depletion [39], suggesting a time window
for supplementation. In the brain-injured patients, another
important question is whether the micronutrients pass the
blood-brain barrier and penetrate the injured area. A microdi-
alysis investigation would be required to address this
question.
A nutritional intervention requires time to achieve an effect, as
shown by prior studies [40]. Nevertheless, positive effects
were indeed observed already during the ICU stay and for the
120-day follow-up: CRP levels decreased faster (significantly
in the cardiac patients) and several other indicators of out-
come had strong trends toward beneficial effects, such as
lengths of mechanical ventilation and of ICU stay. In such sick
patients, who were particularly unwell, this is a considerable
achievement with such a benign and cheap intervention (about
Table 5
Time course of plasma C-reactive protein (mg/L) in all patients and in the three diagnostic categories from admission to day 5
All Day 0 Day 1 Day 2 Day 3 Day 4 Day 5
AOX 49 (0–2,350) 129 (2–359)a 161 (2–364)a 125 (150–399)a,b 100 (16–401)b 80 (14–401)
Placebo 35 (2–176) 141 (2–341)a 174 (2–410)a 156 (2–360)a,b 114 (2–438)b 82 (3–388)
Cardiac surgery
AOX 59 (2–150) 150 (2–359)a 165 (2–317)a 123 (20–367)a 84 (20–319)b 81 (14–243)
Placebo 39 (2–176) 142 (37–341)a 177 (53–410)a 158 (44–360)a 117(26–225)b 81 (19–178)
Trauma
AOX 35 (2–158) 126 (4–282)a,b 164 (9–464)a 146 (41–399)a 146 (41–282)a 114 (41–282)a
Placebo 32 (2–224) 147 (5–327)a,b 201 (46–326)a 174 (34–328)a 161 (21–438)a 117 (34–388)a
Subarachnoid hemorrhage
AOX 32 (0–230) 38 (3–277) 42 (15–184) 67 (16–103) 44 (16–401) 29 (8–401)
Placebo 10 (2–61) 27 (2–185) 22 (2–179) 16 (2–233) 22 (2–233) 21 (2–163)
Data are presented as median (range). C-reactive protein differed over time in the antioxidant (AOX) and placebo groups (two-factor repeated 
analysis of variance: time effect P < 0.0001, group effect P = 0.039, and interaction (time*group) P = 0.16 to not significant [NS]). The attenuation 
of inflammation was most significant in cardiac patients (time effect P < 0.0001, group effect P = 0.41 [NS], and interaction (time*group) P = 
0.0075) and in trauma patients (time effect P < 0.0001, group NS, and time*group NS). No significant change over time was observed in 
subarachnoid hemorrhage patients. The post hoc comparisons were carried out with the Dunnett test (asignificant difference versus baseline within 
groups) and the Scheffe test (bsignificant difference between groups at the same time).
Figure 3
Kaplan-Meier analysis of the length of hospital stay censored for survival according to intervention group in the global population with the detail of  trauma patients Kaplan-Meier analysis of the length of hospital stay censored for survival according to intervention group in the global population with the detail of 
trauma patients. AOX, antioxidant.Critical Care    Vol 12 No 4    Berger et al.
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$50 USD per day). The presumed rationale for this is a rein-
forcement of the endogenous AOX defense, as shown by the
normalized GPX activity in the treatment group.
Rationale for the micronutrient doses and combinations
Selenium may be the cornerstone of the AOX defense system
in acute conditions [13], but other trace elements, and zinc
particularly, are also important players [16]. In our study, the
tested selenium dose (540 μg followed by 270 μg/day) can be
considered low compared with other recent trials [15,41,42].
Nevertheless, it is a very substantial intake compared with the
normal healthy subject requirements of 60 μg per day, and
indeed it did correct the plasma selenium concentrations and
normalize GPX activity. In the ICU, doses ranging between
350 and 1,000 μg for 10 to 15 days have been associated
with clinical benefits [13], while chronic doses of greater than
450 μg/day in the general population have been associated
with a reduction of the activity of the 5' triiodothyronine deiodi-
nase (an indicator of upper safe intakes [43]). The reduction in
renal failure in inflammatory patients from the first Angstwurm
trial was achieved with doses ranging between 100 and 530
μg/day [34] but was not confirmed in subsequent studies with
the same dose [44] or higher doses [15]. The latest trial of
Forceville and colleagues [42] tested a loading dose of 4 mg
followed by 1 mg/day for 2 weeks in 60 septic patients: it did
not show any reduction in renal failure, while length of mechan-
ical ventilation was nonsignificantly prolonged (14 days in the
placebo group versus 19 days in the selenium group), possibly
reflecting an incipient selenium toxicity.
On the other hand, the doses of zinc (2 days of 50 mg then 25
mg/day) and vitamins C, E, and B1 were high compared with
other trials. This combination was motivated by the inclusion of
trauma patients, who develop early negative micronutrient bal-
Figure 4
Selenium, glutathione peroxidase (GPX), and zinc plasma concentrations in trauma and cardiac surgery patients Selenium, glutathione peroxidase (GPX), and zinc plasma concentrations in trauma and cardiac surgery patients. The thick vertical bar next to the y-
axis shows the reference ranges. By two-factor repeated measures analysis of variance, the changes over time and the treatment effect (interaction 
time*group) were strongest in the cardiac group, with P < 0.0001 for the three variables, while in the trauma group, treatment effect was selenium P 
< 0.0001, GPX P = 0.0013, and zinc P = 0.0005. AOX, antioxidant.Available online http://ccforum.com/content/12/4/R101
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ances and low plasma zinc levels. Furthermore, as neurologi-
cal damage was present in two of our diagnostic groups, zinc
was given based on trials in brain-injured patients in whom 30
to 40 mg zinc doses were associated with improved neurolog-
ical outcome [45]. Finally, zinc is involved in tissue repair, and
the improved wound healing in burns observed with 30 mg iv
for 21 days [46] encouraged the addition of this rather large
dose of zinc. Indeed, plasma levels normalized with the supple-
ments and trauma patients appeared to benefit from the
intervention.
Ascorbic acid, alpha-tocopherol, and thiamine were combined
to reinforce the AOX cascade [16]. Vitamin C is strongly
depressed in critical illness, and doses of 3 g per day are
required to normalize plasma concentrations [47]. A loading
dose of 2.7 g for 2 days was therefore adopted. Although
chronic administration to healthy subjects of vitamin E of
doses exceeding 150 mg/day is associated with increased
mortality [48], several trials have delivered 3 g per day for
shorter periods to trauma patients and other critically ill
patients without any detectable side effects [38,49]. Since the
normal daily intake is of the order of 10 mg, our 300 to 600
mg/day dose can be considered at the low range of the high-
dose spectrum. Finally, vitamin B1, though not an AOX but the
coenzyme of all carbohydrate decarboxylation reactions, was
delivered to all patients as deficiency is a recognized problem
in early critical illness [50], with recommendations to deliver
100 mg and up to 300 mg/day.
Study limitations
The supplementation did not achieve a significant reduction of
the primary outcome (that is, early organ failure). There are dif-
ferent possible explanations. First, we did not collect the
SOFA scores after discharge from the ICU – this might have
been valuable. Indeed, the impact of a nutritional intervention
may be detected only after 4 to 5 days. Then, despite the inclu-
sion of 200 patients in three diagnostic categories, the study
was still underpowered. The subgroup analysis is therefore
confronted with an even poorer lack of power. Despite this
problem, all the mean values were oriented in the direction of
a clinical benefit, with trends in favor of the AOX intervention.
These trends nevertheless can be considered only as hypoth-
esis-generating: for example, the trauma patients might benefit
from such an intervention but a larger trial is required. There
was an a priori decision to analyze all patients and then by
diagnostic category as the constitution of these categories
was part of the randomization process. The small SAH group
experienced very few complications and had less inflammation
in agreement with other studies [36], contributing to the
reduction of power. This was worsened by the lower-than-pre-
dicted mortality by either of the outcome scores [25].
Furthermore, despite stratification and randomization, we
observed heterogeneity among the trauma patients. The more
severe brain injuries in the AOX group, which directly impact
on survival, explain the trend to higher mortality in this group
and must be considered in the analysis [51]. This type of bias
is unavoidable, even with strict randomization [35]. Balanced
minimization is an efficient method of ensuring comparable
groups [52]. It consists of determining, at the onset, outcome
factors one would like to see evenly distributed in the groups.
The person in charge of the randomization observes the pro-
gression of these factors during the trial, modifying group allo-
cation if a difference develops. This method was not used in
this study but probably would have avoided this unlucky une-
ven distribution of severity factors. Finally the characteristic of
being a monocentric trial can be considered both a limitation
but also an advantage due to reduction of variability of care.
Conclusion
Selenium-containing AOX micronutrient supplements did not
significantly improve organ dysfunction as assessed by the
SOFA score during the first 5 days. Nevertheless, the inflam-
matory response was significantly blunted as shown by a
lower CRP in the AOX group. The diagnostic categories with
an intense inflammatory response, such as patients with organ
failure after cardiac surgery or major trauma patients, thus
appear good candidates for an AOX intervention, while
patients with limited inflammatory response are not. The opti-
mal dose and combination of micronutrients still remain to be
determined but should include selenium and zinc.
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Key messages
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status is altered on admission in critically ill patients 
with organ failure.
￿  Antioxidant supplements delivered intravenously for 5 
days correct the initial alterations and restore antioxi-
dant defenses, particularly the glutathione peroxidase 
activity.
￿  There is no impact on organ failures (sequential organ 
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but a shorter hospital stay in trauma patients.
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